Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
Portfolio Pulse from Benzinga Newsdesk
Ainos, Inc. (NASDAQ:AIMD) has enrolled the first subject for its clinical study of a VELDONA-based drug aimed at treating feline chronic gingivostomatitis (FCGS). The dosing of the first subject is expected on July 26, 2024. The study aims to enroll 30 subjects by the end of 2024, with the trial report expected in Q1 2025.
July 23, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ainos, Inc. has initiated a clinical study for a VELDONA-based drug targeting feline chronic gingivostomatitis. The study's progress, including the first dosing on July 26, 2024, and expected completion by end-2024, could positively impact AIMD's stock price.
The initiation of the clinical study and the upcoming dosing milestone are significant steps in the development of Ainos' VELDONA-based drug. Successful progress in clinical trials often leads to positive investor sentiment and potential stock price increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100